

| Package | Price per Dose | Price | |
|---|---|---|---|
| 360 pills | β¬0,95 | β¬381,69 β¬343,52 Free shipping | |
| 180 pills | β¬0,98 | β¬196,72 β¬177,05 | |
| 120 pills | β¬1,04 | β¬139,55 β¬125,60 | |
| 90 pills | β¬1,10 | β¬110,97 β¬99,87 | |
| 60 pills | β¬1,21 | β¬80,70 β¬72,63 | |
| 30 pills | β¬1,42 | β¬47,07 β¬42,36 | |
| 360 pills | β¬1,21 | β¬482,59 β¬434,33 Free shipping | |
| 180 pills | β¬1,27 | β¬253,90 β¬228,51 Free shipping | |
| 120 pills | β¬1,39 | β¬184,95 β¬166,46 | |
| 90 pills | β¬1,51 | β¬151,32 β¬136,19 | |
| 60 pills | β¬1,68 | β¬112,65 β¬101,38 | |
| 30 pills | β¬2,01 | β¬67,24 β¬60,52 | |
| 360 pills | β¬1,94 | β¬775,17 β¬697,66 Free shipping | |
| 180 pills | β¬2,12 | β¬423,73 β¬381,36 Free shipping | |
| 120 pills | β¬2,36 | β¬314,43 β¬282,99 Free shipping | |
| 90 pills | β¬2,60 | β¬260,62 β¬234,56 Free shipping | |
| 60 pills | β¬2,97 | β¬198,41 β¬178,56 | |
| 30 pills | β¬3,59 | β¬119,37 β¬107,44 | |
| 360 pills | β¬2,42 | β¬968,55 β¬871,70 Free shipping | |
| 180 pills | β¬2,74 | β¬548,17 β¬493,35 Free shipping | |
| 120 pills | β¬3,12 | β¬415,32 β¬373,79 Free shipping | |
| 90 pills | β¬3,48 | β¬348,06 β¬313,26 Free shipping | |
| 60 pills | β¬4,21 | β¬280,80 β¬252,72 Free shipping | |
| 30 pills | β¬5,66 | β¬188,32 β¬169,48 |
Ropinirole is a dopamine agonist of the non-ergoline class that selectively stimulates dopamine D2-like receptors, principally D2 and D3, to enhance dopaminergic transmission in the striatum. It is used primarily to treat symptoms of Parkinson disease and restless legs syndrome.
Orally administered, ropinirole acts as a direct receptor agonist with a pharmacologic profile suited to symptomatic management. It is available in immediate-release formulations and, in some regions, extended-release forms to allow flexible dosing schedules.
Ropinirole is approved for the symptomatic management of Parkinson disease, including initial therapy in mild to moderate disease and as an adjunct to levodopa in advanced stages. It helps reduce motor fluctuations and bradykinesia by substituting for diminished dopaminergic signaling.
In restless legs syndrome, ropinirole reduces nocturnal sensations and the urge to move, improving sleep quality and daytime function. It should be used as part of a comprehensive management plan and is not curative but aims to restore dopaminergic balance during symptoms.
Dosing is individualized and titration is gradual. In Parkinson disease, initiation commonly starts at 0.25 mg three times daily, with weekly increases as tolerated to balance symptom control and tolerability. After adjustment, clinicians may continue titration to achieve symptom relief while limiting adverse effects.
For restless legs syndrome, dosing is started at low levels and adjusted based on response and tolerability, with consideration of bedtime administration for some formulations. Do not alter the schedule without medical advice, as abrupt changes can worsen symptoms or side effects.
Food effects are modest; ropinirole may be taken with or without food. If nausea occurs, taking the dose with a light meal can help. If a dose is missed, take it as soon as remembered unless it is nearly time for the next scheduled dose; do not double up. Store at room temperature, away from moisture, heat, and light, and keep out of reach of children. Dispose of any unused tablets per local guidelines and avoid using after the expiration date.
Common adverse effects include nausea, dizziness, fatigue, and daytime sleepiness. Orthostatic hypotension may occur, especially after starting therapy or with dose increases, leading to lightheadedness on standing.
Less common but important effects include impulse control disorders (such as compulsive gambling or eating), hallucinations, confusion, and sudden sleep episodes. Seek medical attention if these occur, or if there is severe swelling, chest pain, or trouble breathing.
Consult a clinician before starting ropinirole and whenever considering stopping the medication. Inform the prescriber about all medicines, including over-the-counter products, as ropinirole can interact with other agents. Discuss use in pregnancy, breastfeeding, and with liver or kidney impairment, as dose adjustments may be needed.
Ongoing medical supervision is advised to monitor response and tolerability. Contact the clinician if Parkinsonian symptoms worsen, if sleep disturbances persist, or if new behavioral changes appear. Do not abruptly discontinue ropinirole; taper under medical guidance if a dose is being stopped.
14β21 days. Free from β¬182,34 .
5β9 days. β¬27,35
β10% when paying with cryptocurrency.
β10% on all repeat orders.
All orders are packed in neutral, unbranded boxes with no product name on the outside.
